Table I.
Description of the eight cancer GWAS included in this analysisa
| Cancer type (dbGaP study accession) | Cases (n) | Controls (n) | Ethnicity | Source of participants (substudies) | No. of SNPsb | Covariates |
|---|---|---|---|---|---|---|
| ESCC (phs000361. v1.p1) | 1942 | 2111 | Asian | One case–control and one case-only study: Shanxi (China); one cohort study: NITs (China) | 2272 | Age, sex and substudy |
| GC (phs000361.v1.p1) | 1758 | 2111 | Asian | One case–control and one case-only study: Shanxi (China); one cohort study: NITs (China) | 2267 | Age, sex and substudy |
| BrC (phs000147. v1.p1) | 1145 | 1142 | Caucasian | One cohort study: NHS (USA) | 2470 | Age and three PCs |
| LC (phs000336.v1.p1) | 3782 | 3837 | Caucasian | Three cohort studies: ATBC (Finland), CPS II (USA) and PLCO (USA) | 2451 | Age, sex, substudy and four PCs |
| RCC (phs000351. v1.p1) | 1311 | 3424 | Caucasian | Three cohort studies: ATBC (Finland), CPS II (USA) and PLCO (USA); one case– control study: USKC (USA) | 2600 | Sex, substudy and two PCs |
| BC (phs000346.v1.p1) | 2811 | 3241 | Caucasian | Two case–control studies: SBCS (Spain) and NEBCS-ME, VT (USA); two cohort studies: ATBC (Finland) and CPS II (USA) | 3674 | Age, sex, substudy and 10 PCs |
| PrC (phs000207. v1.p1) | 1151 | 1101 | Caucasian | One cohort study: PLCO (USA) | 2509 | Age and 10 PCs |
| PanC (phs000206. v3.p2) | 2440 | 2452 | Caucasian, Asian | 12 cohort studies (USA, unless noted otherwise): ATBC (Finland), CLUE II, CPS II, EPIC, HPFS, NHS, NYU- WHS, PHS, PLCO, SMWHS (China), WHI and WHS; two case–control studies (USA): Mayo and MDA. | 2517 | Age, sex, substudy and eight PCs |
CGEMS, Cancer Genetic Markers of Susceptibility; CLUE, Give Us a Clue to Cancer and Heart Disease Study; CPS, the American Cancer Society Cancer Prevention Study; dbGaP, database of Genotype and Phenotype; EPIC, European Prospective Investigation Into Cancer and Nutrition Study; HPFS, Health Professionals Follow-up Study; Mayo, Mayo Clinic Molecular Epidemiology Case–Control Study; MDA, MD Anderson Cancer Center; NEBCS-ME, VT, New England Bladder Cancer Study-Maine, Vermont; NHS, Nurses’ Health Study; NIT, Nutrition Intervention Trial; NYU-WHS, The New York University Women’s Health Study; PHS, Physicians Health Study; PC, principal components; SBCS, Spanish Bladder Cancer Study; Shanxi, Shanxi UGI Cancer Genetic Project; SMWHS, Shanghai Men’s and Women’s Health Study; USKC, National Cancer Institute United States Kidney Cancer Study; WHI, Women’s Health Initiative; WHS, Womens’ Heath Study.
aData on ESCC and GC were provided by the study principal investigator (P.R.T.) which included additional subjects after the initial GWAS scan. Other discrepancies between numbers here and those shown in dbGaP are due to the limit of the authors’ data access or the applied quality control criteria.
bSNPs without deviation from Hardy–Weinberg equilibrium (P > 10−7) in controls, with minor allele frequency >0.01 in cases and controls combined, and with completion rate >0.90 in cases and controls combined.